Literature DB >> 33413365

A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis.

Jie Mei1, Junying Xu1, Xuejing Yang1, Dingyi Gu1, Weijian Zhou1, Huiyu Wang2, Chaoying Liu3.   

Abstract

Emerging evidence has revealed that the removal of N-linked glycosylation could enhance PD-L1 detection. However, whether PD-L1 antibodies against different epitopes of PD-L1 antigens responding to deglycosylation has not been characterized. In this study, we compared natural and deglycosylated PD-L1 expression in lung cancer (LuCa) using a panel of PD-L1 antibodies (28-8, CAL10, 73-10 and SP142). We found that removal of N-linked glycosylation markedly enhanced PD-L1 detection when the 28-8, CAL10 and SP142 monoclonal antibodies (mAbs) were used but slightly inhibited PD-L1 detection when the 73-10 mAb was used. Moreover, for the CAL10 and SP142 mAbs, deglycosylated PD-L1 levels showed stronger correlations with the response to anti-PD-1 therapy. Overall, our research provides a comprehensive insight into the application of deglycosylated PD-L1 detection, which expands the clinical significance of this established strategy in LuCa.

Entities:  

Year:  2021        PMID: 33413365      PMCID: PMC7789157          DOI: 10.1186/s12943-020-01304-4

Source DB:  PubMed          Journal:  Mol Cancer        ISSN: 1476-4598            Impact factor:   27.401


  10 in total

1.  Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.

Authors:  Heng-Huan Lee; Ying-Nai Wang; Weiya Xia; Chia-Hung Chen; Kun-Ming Rau; Leiguang Ye; Yongkun Wei; Chao-Kai Chou; Shao-Chun Wang; Meisi Yan; Chih-Yen Tu; Te-Chun Hsia; Shu-Fen Chiang; K S Clifford Chao; Ignacio I Wistuba; Jennifer L Hsu; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Cancer Cell       Date:  2019-07-18       Impact factor: 31.743

Review 2.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 3.  Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).

Authors:  J Nicholas Bodor; Yanis Boumber; Hossein Borghaei
Journal:  Cancer       Date:  2019-11-06       Impact factor: 6.860

4.  Deglycosylated PD-L1 might be a better biomarker.

Authors:  Peter Sidaway
Journal:  Nat Rev Clin Oncol       Date:  2019-10       Impact factor: 66.675

5.  PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.

Authors:  Ming Sound Tsao; Keith M Kerr; Mark Kockx; Mary-Beth Beasley; Alain C Borczuk; Johan Botling; Lukas Bubendorf; Lucian Chirieac; Gang Chen; Teh-Ying Chou; Jin-Haeng Chung; Sanja Dacic; Sylvie Lantuejoul; Mari Mino-Kenudson; Andre L Moreira; Andrew G Nicholson; Masayuki Noguchi; Giuseppe Pelosi; Claudia Poleri; Prudence A Russell; Jennifer Sauter; Erik Thunnissen; Ignacio Wistuba; Hui Yu; Murry W Wynes; Melania Pintilie; Yasushi Yatabe; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2018-05-22       Impact factor: 15.609

6.  Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.

Authors:  Joseph McLaughlin; Gang Han; Kurt A Schalper; Daniel Carvajal-Hausdorf; Vasiliki Pelekanou; Jamaal Rehman; Vamsidhar Velcheti; Roy Herbst; Patricia LoRusso; David L Rimm
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

Review 7.  The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.

Authors:  Suzanne Ostrand-Rosenberg; Lucas A Horn; Samuel T Haile
Journal:  J Immunol       Date:  2014-10-15       Impact factor: 5.422

8.  Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.

Authors:  Rhiannon K Beckers; Christina I Selinger; Ricardo Vilain; Jason Madore; James S Wilmott; Kate Harvey; Anne Holliday; Caroline L Cooper; Elizabeth Robbins; David Gillett; Catherine W Kennedy; Laurence Gluch; Hugh Carmalt; Cindy Mak; Sanjay Warrier; Harriet E Gee; Charles Chan; Anna McLean; Emily Walker; Catriona M McNeil; Jane M Beith; Alexander Swarbrick; Richard A Scolyer; Sandra A O'Toole
Journal:  Histopathology       Date:  2016-01-13       Impact factor: 5.087

Review 9.  PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.

Authors:  Junzo Hamanishi; Masaki Mandai; Noriomi Matsumura; Kaoru Abiko; Tsukasa Baba; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2016-02-22       Impact factor: 3.402

10.  Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.

Authors:  Chia-Wei Li; Seung-Oe Lim; Weiya Xia; Heng-Huan Lee; Li-Chuan Chan; Chu-Wei Kuo; Kay-Hooi Khoo; Shih-Shin Chang; Jong-Ho Cha; Taewan Kim; Jennifer L Hsu; Yun Wu; Jung-Mao Hsu; Hirohito Yamaguchi; Qingqing Ding; Yan Wang; Jun Yao; Cheng-Chung Lee; Hsing-Ju Wu; Aysegul A Sahin; James P Allison; Dihua Yu; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Nat Commun       Date:  2016-08-30       Impact factor: 14.919

  10 in total
  8 in total

1.  De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.

Authors:  Fu Ou-Yang; Chung-Liang Li; Chia-Chi Chen; Yi-Chun Shen; Sin-Hua Moi; Chi-Wen Luo; Wei-Ya Xia; Ying-Nai Wang; Heng-Huan Lee; Lu-Hai Wang; Shao-Chun Wang; Mei-Ren Pan; Ming-Feng Hou; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

2.  HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.

Authors:  Jie Mei; Guanyu Jiang; Yundi Chen; Yongrui Xu; Yuan Wan; Ruo Chen; Feng Liu; Wenjun Mao; Mingfeng Zheng; Junying Xu
Journal:  BMC Cancer       Date:  2022-07-06       Impact factor: 4.638

Review 3.  Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.

Authors:  Tao Wang; Desirée Denman; Silvia M Bacot; Gerald M Feldman
Journal:  Biomedicines       Date:  2022-05-20

4.  Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer.

Authors:  Jiayue Yang; Zhen Tian; Han Gao; Fan Xiong; Cuiping Cao; Jiaojiao Yu; Wei Shi; Qiang Zhan; Cheng Yang
Journal:  BMC Cancer       Date:  2022-05-27       Impact factor: 4.638

5.  The B7H4-PDL1 classifier stratifies immuno-phenotype in cervical cancer.

Authors:  Lingyan Chen; Jianfeng Dong; Zeying Li; Yu Chen; Yan Zhang
Journal:  Cancer Cell Int       Date:  2022-01-04       Impact factor: 5.722

6.  An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response.

Authors:  Ying-Nai Wang; Heng-Huan Lee; Yongkun Wei; Yu-Yi Chu; Weiya Xia; Michael Wang; Dihua Yu; Mien-Chie Hung
Journal:  STAR Protoc       Date:  2022-02-25

7.  The Clinical Significance of Deglycosylated PD-L1 Level Detection Using 28-8 Monoclonal Antibody in Lung Adenocarcinoma.

Authors:  Huiyu Wang; Dingyi Gu; Datian Chen; Jie Mei; Xuejing Yang; Junli Ding; Junying Xu; Meilin Wang; Chaoying Liu; Dong Hua
Journal:  Int J Gen Med       Date:  2022-09-19

8.  Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon Cancer: Validation Research Based on Immunohistochemistry Analysis.

Authors:  Junying Xu; Xuejing Yang; Yong Mao; Jie Mei; Huiyu Wang; Junli Ding; Dong Hua
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.